Plasma-based Colorectal Cancer Screening Research & Development

Inclusion Criteria: Group 1 * Willing and able to sign an Informed Consent and adhere to study requirements. * Subjects with colorectal cancer preferably detected by screening (any guideline recommended modality). * Colonoscopy diagnosis of colorectal cancer (CRC).\* * Blood sampling a minimum of 7 days after colonoscopy and before resection surgery. * = Strong clinical suspicion of colorectal carcinoma is also acceptable for subject enrollment; Case must have a confirmed diagnosis after surgery of CRC and be accompanied by a complete final pathology report. Inclusion Criteria: Group 2 * Willing and able to sign an Informed Consent and adhere to study requirements. * Eligible for colorectal cancer screening colonoscopy. * 45 - 84 years of age at blood sampling. * Able to provide blood sample within up to 2 weeks prior to bowel prep and colonoscopy. Exclusion Criteria: Group 1 * Subject with curative biopsy during colonoscopy. * Current neoadjuvant treatment. * Current diagnosis of any cancer other than CRC, except non-melanoma skin cancer. * Known infection with HIV, HBV or HCV. Exclusion Criteria: Group 2 * Previous personal history of CRC, adenomatous polyps \>10mm or sessile serrated adenomas (polyps). * Familial risk for colorectal cancer (1 or more 1st degree relatives with CRC; known HNPCC or FAP). * History of inflammatory bowel disease. * Current neoadjuvant treatment. * Current diagnosis of any cancer other than CRC, except non-melanoma skin cancer. * infection with HIV, HBV or HCV.